Detalhe da pesquisa
1.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
2.
Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
Vaccine
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704253
3.
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.
NPJ Vaccines
; 9(1): 10, 2024 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38184681
4.
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens.
Front Immunol
; 14: 1193079, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299155
5.
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.
Sci Transl Med
; 15(704): eadf1782, 2023 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37437014
6.
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics.
Front Immunol
; 13: 984323, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36072606
7.
Impact of a blood-stage vaccine on Plasmodium vivax malaria.
medRxiv
; 2022 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35664997
8.
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly.
JCI Insight
; 6(23)2021 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34609964